Channing Capital Management LLC Takes $6.19 Million Position in Becton, Dickinson and Company (NYSE:BDX)

Channing Capital Management LLC bought a new position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 25,374 shares of the medical instruments supplier's stock, valued at approximately $6,187,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Clearstead Trust LLC grew its holdings in Becton, Dickinson and Company by 1,714.0% in the fourth quarter. Clearstead Trust LLC now owns 2,340 shares of the medical instruments supplier's stock worth $571,000 after purchasing an additional 2,211 shares during the period. National Bank of Canada FI grew its holdings in Becton, Dickinson and Company by 83.7% in the fourth quarter. National Bank of Canada FI now owns 309,963 shares of the medical instruments supplier's stock worth $76,006,000 after purchasing an additional 141,221 shares during the period. AJOVista LLC acquired a new stake in Becton, Dickinson and Company in the fourth quarter worth $126,000. Sapient Capital LLC acquired a new position in shares of Becton, Dickinson and Company during the fourth quarter valued at about $1,280,000. Finally, Axxcess Wealth Management LLC grew its holdings in shares of Becton, Dickinson and Company by 17.6% during the fourth quarter. Axxcess Wealth Management LLC now owns 8,486 shares of the medical instruments supplier's stock valued at $2,069,000 after buying an additional 1,270 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company's stock.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the completion of the transaction, the senior vice president now owns 2,276 shares of the company's stock, valued at approximately $542,348.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, EVP Michael David Garrison sold 1,715 shares of the business's stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the transaction, the executive vice president now owns 5,381 shares of the company's stock, valued at $1,252,750.61. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Thomas J. Spoerel sold 282 shares of the business's stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $238.29, for a total value of $67,197.78. Following the transaction, the senior vice president now directly owns 2,276 shares of the company's stock, valued at approximately $542,348.04. The disclosure for this sale can be found here. Insiders own 0.31% of the company's stock.

Becton, Dickinson and Company Stock Performance

BDX stock traded up $1.92 during mid-day trading on Monday, hitting $236.60. The company had a trading volume of 1,255,426 shares, compared to its average volume of 1,412,024. The firm has a market cap of $68.38 billion, a PE ratio of 52.11, a price-to-earnings-growth ratio of 1.92 and a beta of 0.45. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.41. Becton, Dickinson and Company has a 12 month low of $229.40 and a 12 month high of $287.32. The stock's fifty day moving average price is $238.35 and its two-hundred day moving average price is $240.12.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $3.17 EPS for the quarter, topping the consensus estimate of $2.97 by $0.20. The business had revenue of $5.05 billion for the quarter, compared to analyst estimates of $5.04 billion. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The company's revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.86 earnings per share. On average, analysts forecast that Becton, Dickinson and Company will post 13.04 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Monday, June 10th will be paid a $0.95 dividend. The ex-dividend date of this dividend is Monday, June 10th. This represents a $3.80 dividend on an annualized basis and a yield of 1.61%. Becton, Dickinson and Company's dividend payout ratio is 83.70%.

Analyst Ratings Changes

Separately, Barclays lifted their price objective on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an "overweight" rating in a report on Monday. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $281.40.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.